UNSPSC 51271614: Octacaine

This classification denotes an anesthetic agent with the molecular formula C14H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5BZF8S8IL5, chemically known as butyranilide, 3-(diethylamino)- but generally known as octacaine, which bears US NIH Compound Identifier 26329. European Medicines Agency schedules Octacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09401MIG. The term OCTACAINE is an International Non-Proprietary Name.

UNSPSC 51271614 Octacaine, a Commodity code, represents local anesthetic pharmaceuticals procured through multi-state cooperative purchasing agreements and direct state procurement channels. State and local governments acquire octacaine primarily as a generic pharmaceutical input within broader pharmaceutical supply contracts that establish pricing and distribution mechanisms across participating jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a primary issuing body for this code, soliciting through cooperative purchasing vehicles that aggregate demand across state and local healthcare facilities. Recent activity shows state procurement offices and health systems using RFP structures to establish multi-award pharmaceutical supply agreements where octacaine and similar local anesthetics are acquired alongside other generic pharmaceuticals and OTC products through authorized pharmaceutical wholesalers.

MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products (Solicitation S1070000015802) represents the most recent opportunity, with proposals due March 26, 2026. The solicitation encompasses participating facilities across Minnesota and Oregon, requiring vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and to demonstrate cGMP compliance and Drug Supply Chain Security Act (DSCSA) certification. Evaluation criteria prioritize price competitiveness (75 percent) and fixed pricing for the contract term (10 percent), with administrative fees of 3 percent on all purchases and performance penalties ranging from $200 to $1,500 per violation. The contract term runs two years from July 1, 2026, with optional MMCAP extensions, requiring vendors to maintain $5 million commercial general liability insurance and submit product information including NDC codes, SKUs, and manufacturing locations through the ePro procurement system by the March 26 deadline. Questions close February 18, 2026.